Kemwell Biopharma, a contract development and manufacturing service provider, has manufactured and supplied drug substance using its state-of-the-art mammalian cell culture plant in India for clinical trials that will be performed by its customer in the U.S. for an IND filing. The customer has received IND approval and is commencing Phase 1 clinical trials.

Kemwell provided a fully integrated solution including technology transfer, process optimization, scale-up, manufacturing of toxicology materials and cGMP manufacturing of drug substance clinical materials.

“Partnering with a number of well-known technology providers, Kemwell aims to establish itself as a leading player in the one-stop-shop biopharmaceutical contract manufacturing space,” said Anurag Bagaria, managing director, Kemwell. “Our endeavor is to capitalize on the eastern advantage of a cost-friendly environment while offering all the western advantages of quality and innovation. As pharmaceutical companies are now concentrating their R&D budgets on large molecule products, we are seeing increased demand in our biotech services.”

Kemwell’s biotechnology capabilities include process development and manufacturing of drug substances and drug products for toxicology in 80L scale bioreactors, as well as for cGMP clinical and commercial manufacturing in 400L and 2000L bioreactors with corresponding downstream processing, fill & finish in liquid and lyophilized vials and integrated quality management.

Kemwell Biopharma is located in Bangalore, India and is a pure play contract development and manufacturing service provider for biopharmaceuticals. Kemwell’s state-of-the-art facility is one of the largest available capacities for contract manufacturing of monoclonal antibodies and protein therapeutics derived from mammalian cell culture in India.